included small cohorts or were spread over long periods, leading to time bias. 5 , 15 , 16 In other studies, severe sepsis and septic shock are reported together. 5 , 14 This article reports on the short-term outcomes and the independent predictors of 28
Search Results
Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria
Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates
Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database
Naleen Raj Bhandari, Lisa M. Hess, Dan He, and Patrick Peterson
might not be treated in a way concordant with their test result and treatment guidelines, and a limited number of studies have investigated this in association with eventual survival outcomes. A study based on administrative claims data from 2010 to 2014
Breast Cancer in Adolescents and Young Adults: A Review With a Focus on Biology
Jill R. Tichy, Elgene Lim, and Carey K. Anders
-related survival over the past 2 decades. 2 Several factors may explain the poor outcomes observed in this population, which may include a limited understanding of the biology of these cancers, inadequate clinical trial representation, and unique psychosocial and
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal
Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp
that older adults represent less than one-third of cancer clinical trial participants. Moreover, according to a recent meta-analysis of >150 clinical trials, only between 40% and 70% of clinical trials reported on the outcomes of older adult subgroups
Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus
Nivedita Arora, Arjun Gupta, Hong Zhu, Alana Christie, Jeffrey J. Meyer, Saad A. Khan, and Muhammad S. Beg
(RT) considered first-line therapy, and salvage surgery used for resistant or recurrent disease. 8 Race and sex disparities related to access to care and outcomes have been studied for several malignancies, including pancreatic, breast, and lung
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database
Johannes Uhlig, Michael Cecchini, Amar Sheth, Stacey Stein, Jill Lacy, and Hyun S. Kim
prevalence of microsatellite and KRAS status in stage IV CRC using a large-scale US national database and assessed their effect on outcomes of patients with CRC. Materials and Methods This study received approval from the Yale School of Medicine
Decline in Smartphone-Assessed Physical Activity Level is Associated With Clinical Outcomes in Phase I/II Clinical Cancer Trials
Calvin G. Brouwer, Joeri A.J. Douma, Evelien J.M. Kuip, Sonja Zweegman, Niels W.C.J van de Donk, Maria T.E. Hopman, Myra E. van Linde, Henk M.W. Verheul, and Laurien M. Buffart
physical function could help identify potential harm of treatment and may be prognostic for clinical outcomes. 8 Previous pilot studies have shown that it is feasible to use wearable devices to monitor physical activity levels of patients receiving cancer
Systemic Treatment Strategies and Outcomes of Patients With Synchronous Peritoneal Metastases of Gastric Origin: A Nationwide Population-Based Study
Niels A.D. Guchelaar, Bo J. Noordman, Marion W. Welten, Myron T. van Santen, Micha J. de Neijs, Stijn L.W. Koolen, Rob H.A. Verhoeven, Esther Oomen-de Hoop, Pieter C. van der Sluis, Sjoerd M. Lagarde, Hanneke W.M. van Laarhoven, Ignace H.J.T. de Hingh, Geert-Jan Creemers, Bianca Mostert, Bas P.L. Wijnhoven, and Ron H.J. Mathijssen
expression. 5 – 7 Triplet therapy has been suggested to improve treatment outcomes, but its survival benefit is under debate and triplets are associated with increased toxicity. 8 , 9 Because no optimal combination regimen has been defined yet, substantial
Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study
Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow
in patients with ovarian cancer Describe the impact on patient outcomes related to refusal of recommended chemotherapy in patients with ovarian cancer Background Ovarian cancer remains the deadliest gynecologic malignancy, with
HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D
Radhakrishnan Ramchandren, Stephen M. Ansell, Philippe Armand, Andreas Engert, Fiona Taylor, Kim Cocks, Clara Chen, Bryan Bennett, Alejandro Moreno-Koehler, Adam Roeder, Anne Sumbul, Mariana Sacchi, and David Cella
checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018
